Nicotinamide ribonucleoside
Phase 2Small molecule
Nicotinamide ribonucleoside is one of 12 small molecule programs targeting Ataxia-telangiectasia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Ataxia-Telangiectasia
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Glucophage
EMD SeronoApproved
Amantadine Sulphate
SSheba Medical Center
Approved
Lioresal
NovartisPhase 1
N-Acetyl-L-Leucine
IIntraBio Inc
Phase 3
IB1001
MMedexus Pharma, Inc.
Phase 2
Conjugated Pneumococcal Vaccine
IInstitute of Child Health
Phase 3
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Nicotinamide ribonucleoside
UUniversity Hospital, Akershus
Phase 2
Prevenar
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nicotinamide ribonucleoside. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity Hospital, Akershus